CN1067082C - 用于治疗和预防内毒素血症的取代的脂多糖 - Google Patents

用于治疗和预防内毒素血症的取代的脂多糖 Download PDF

Info

Publication number
CN1067082C
CN1067082C CN96195890A CN96195890A CN1067082C CN 1067082 C CN1067082 C CN 1067082C CN 96195890 A CN96195890 A CN 96195890A CN 96195890 A CN96195890 A CN 96195890A CN 1067082 C CN1067082 C CN 1067082C
Authority
CN
China
Prior art keywords
branched
alkyl
compound
straight
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN96195890A
Other languages
English (en)
Chinese (zh)
Other versions
CN1192216A (zh
Inventor
W·J·克赖斯特
D·P·罗西尼奥尔
小林精一
川田力
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23833509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1067082(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of CN1192216A publication Critical patent/CN1192216A/zh
Application granted granted Critical
Publication of CN1067082C publication Critical patent/CN1067082C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
CN96195890A 1995-06-05 1996-06-05 用于治疗和预防内毒素血症的取代的脂多糖 Expired - Lifetime CN1067082C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/461,675 US5750664A (en) 1995-06-05 1995-06-05 Substituted liposaccharides useful in the treatment and prevention of endotoxemia
US08/461,675 1995-06-05

Publications (2)

Publication Number Publication Date
CN1192216A CN1192216A (zh) 1998-09-02
CN1067082C true CN1067082C (zh) 2001-06-13

Family

ID=23833509

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96195890A Expired - Lifetime CN1067082C (zh) 1995-06-05 1996-06-05 用于治疗和预防内毒素血症的取代的脂多糖

Country Status (21)

Country Link
US (8) US5681824A (OSRAM)
EP (1) EP0853627B1 (OSRAM)
JP (3) JP4009318B2 (OSRAM)
KR (1) KR100416335B1 (OSRAM)
CN (1) CN1067082C (OSRAM)
AT (1) ATE258185T1 (OSRAM)
AU (1) AU707779C (OSRAM)
CA (1) CA2223140C (OSRAM)
DE (1) DE69631376T2 (OSRAM)
DK (1) DK0853627T3 (OSRAM)
ES (1) ES2214543T3 (OSRAM)
HU (1) HU221342B1 (OSRAM)
IL (2) IL122251A0 (OSRAM)
MX (1) MX9709502A (OSRAM)
NO (1) NO310239B1 (OSRAM)
NZ (1) NZ312299A (OSRAM)
PT (1) PT853627E (OSRAM)
RU (1) RU2170738C2 (OSRAM)
TW (1) TW366345B (OSRAM)
WO (1) WO1996039411A1 (OSRAM)
ZA (1) ZA964666B (OSRAM)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417172B1 (en) * 1995-06-05 2002-07-09 Eisai Co., Ltd. Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
US5681824A (en) * 1995-06-05 1997-10-28 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
WO1998001139A1 (fr) * 1996-07-03 1998-01-15 Eisai Co., Ltd. Produits pour injection contenant des analogues de lipides a et procede de preparation correspondant
US6828155B1 (en) 1998-09-01 2004-12-07 Eisai Co., Ltd. Method for evaluating lipid a analog-containing injections
EP1158990B1 (en) * 1999-01-14 2007-10-17 Eisai R&D Management Co., Ltd. Use of e5564 for the treatment of sepsis by intravenous infusion
US20030130212A1 (en) * 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US7915238B2 (en) * 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
TW527358B (en) 1999-02-10 2003-04-11 Sankyo Co Ether type lipid A1 position carboxylic acid analogue
US20050101549A1 (en) * 2000-01-14 2005-05-12 Melvyn Lynn Prevention and treatment of endotoxemia and related complications associated with surgery
JP2003524638A (ja) * 2000-01-14 2003-08-19 エーザイ株式会社 手術に伴う内毒素血症及び関連する合併症の予防及び治療
US6906042B2 (en) 2000-02-18 2005-06-14 Eisai Co., Ltd. Micelles
US6861512B2 (en) * 2000-03-01 2005-03-01 Eisai Co., Ltd. Separation of olefinic isomers
AU2001275520A1 (en) * 2000-06-09 2001-12-17 Eisai Co. Ltd. Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion
US20030105033A1 (en) * 2000-06-09 2003-06-05 Rossignol Daniel P. Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion
WO2002088062A1 (en) * 2001-04-23 2002-11-07 Eisai Co., Ltd. Process for preparation of alcohol derivatives
JPWO2002088072A1 (ja) * 2001-04-23 2004-08-12 エーザイ株式会社 アルキレン化合物の製造方法
US20040198652A1 (en) * 2001-04-24 2004-10-07 Carter J. Paul Methods and compositions for preventing and treating septic shock and endotoxemia
US7759323B2 (en) * 2001-05-22 2010-07-20 Eisai R & D Management Co., Ltd. Highly purified antiendotoxin compound
DE10125179A1 (de) * 2001-05-23 2002-12-05 Laves Ralph Georg Verwendung von LPS zur Behandlung intestinaler Entzündungsprozesse
WO2003013440A2 (en) * 2001-08-10 2003-02-20 Eisai Co., Ltd. Treatment and prevention of heat shock protein-associated diseases and conditions
US7727974B2 (en) * 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
WO2003050137A2 (en) * 2001-12-11 2003-06-19 David Schwartz Toll-like receptor 4 mutations
AU2002950657A0 (en) * 2002-08-08 2002-09-12 Alchemia Limited Derivatives of monosaccharides for drug discovery
AU2002951995A0 (en) * 2002-10-11 2002-10-31 Alchemia Limited Classes of compounds that interact with gpcrs
WO2004058788A1 (ja) * 2002-12-24 2004-07-15 Sankyo Company, Limited 右糖グルコースリピドa類縁体
CN101080234A (zh) * 2003-01-06 2007-11-28 科里克萨有限公司 一些氨烷基氨基葡糖苷磷酸酯化合物和它们的用途
KR100856819B1 (ko) * 2003-01-28 2008-09-05 아카데미슈 지켄후이스 라이덴 Ｌｌ―37 유래의 펩티드성 독소 억제제
JP4773336B2 (ja) * 2003-02-20 2011-09-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｌｐｓアンタゴニストｂ１２８７およびその立体異性体の調製のための試薬および方法
AU2004218358A1 (en) * 2003-03-05 2004-09-16 Eisai R&D Management Co., Ltd. Compositions and methods for preventing and treating endotoxin-related diseases and conditions
WO2005027826A2 (en) * 2003-07-14 2005-03-31 Eisai, Co, Ltd. Methods and treating severe acute respiratory syndrome
US20050208470A1 (en) 2003-12-16 2005-09-22 University Of Massachusetts Toll-like receptor assays
BRPI0506671A (pt) * 2004-01-08 2007-05-15 Sankyo Co análogo de levulose glicose-lipìdio
JP5185813B2 (ja) 2005-04-26 2013-04-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 癌免疫治療のための組成物および方法
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
EP1895842A4 (en) * 2005-06-17 2009-06-03 Univ Rochester METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE MEMORY BY BLOCKING INTRAHEPATIC ERASURE OF ACTIVE T CELLS
JP5118968B2 (ja) * 2005-08-31 2013-01-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 リピッドａ類縁体の製造方法
AU2006285926B2 (en) * 2005-08-31 2012-05-24 Eisai R & D Management Co., Ltd. Process for production of lipid A analogue
US7943588B2 (en) 2006-03-28 2011-05-17 Trustees Of Dartmouth College Method for preventing or treating neuropathic pain
WO2008059307A2 (en) * 2006-11-16 2008-05-22 Om Pharma Functionalized beta 1,6 glucosamine disaccharides and process for their preparation
ES2392890T3 (es) * 2006-11-22 2012-12-14 Eisai R&D Management Co., Ltd. Sal sódica de un compuesto disacarídico, procedimiento para la producción de la misma y uso de la misma
CA2669674C (en) 2006-11-22 2016-05-17 Eisai R&D Management Co., Ltd. Sodium salt of disaccharide compound, method for producing the same, and use of the same
JP5358450B2 (ja) 2006-11-23 2013-12-04 カディラ ファーマシューティカルズ リミテッド ポリ−ｔｌｒアンタゴニスト
WO2011035026A1 (en) * 2009-09-16 2011-03-24 Heidi Ehrentraut Methods for treating myocardial disorders
WO2011038537A1 (zh) * 2009-09-29 2011-04-07 上海南方基因科技有限公司 败血症以及败血症休克的预测、预防和治疗方法及试剂盒
GB201013785D0 (en) 2010-08-17 2010-09-29 Ucl Business Plc Treatment
JP2012246470A (ja) 2011-05-31 2012-12-13 Sharp Corp 半導体ナノ粒子の製造方法、半導体ナノ粒子、ならびにこれを用いた蛍光体
WO2013093631A2 (en) * 2011-12-22 2013-06-27 Nanoco Technologies, Inc. Surface modified nanoparticles
KR20140139063A (ko) 2012-03-28 2014-12-04 유니버시티 오브 매릴랜드, 발티모어 오르토믹소바이러스 감염 치료를 위한 에리토란 또는 그의 제약학상 허용가능한 염의 투여
WO2014113048A1 (en) * 2013-01-18 2014-07-24 Loma Linda University Compositions and methods for diagnosing and treating sepsis
EP3019200B1 (en) 2013-07-11 2022-03-23 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
US9584991B1 (en) * 2014-06-19 2017-02-28 Isaac S. Daniel Method of communicating and accessing social networks using interactive coded messages
CN108884121B (zh) * 2016-03-30 2022-05-31 阿尤维斯研究有限公司 新组合物和治疗方法
US10570074B2 (en) 2016-09-14 2020-02-25 Genomatica, Inc. 1,3-fatty diol compounds and derivatives thereof
EP3512508B1 (en) * 2016-09-16 2022-03-16 Eisai R&D Management Co., Ltd. Method of use of eritoran as a tlr4 antagonist for treatment of ebola and marburg disease
CN112930184B (zh) * 2018-12-17 2024-07-12 卫材R&D管理有限公司 包含脂质体的配制品
WO2021207218A1 (en) 2020-04-06 2021-10-14 Eisai R&D Management Co., Ltd. Treatment of nidovirales infection with eritoran
CN113527396B (zh) * 2020-04-17 2024-02-02 上海医药工业研究院 一种疫苗佐剂mpla的中间体、合成及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4495346A (en) * 1981-03-30 1985-01-22 Wisconsin Alumni Research Foundation Method of preparing a disaccharide

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
JPS6153295A (ja) * 1984-08-24 1986-03-17 Dai Ichi Seiyaku Co Ltd ジサツカライド誘導体
US5066794A (en) * 1984-08-24 1991-11-19 Daiichi Pharmaceutical Co., Ltd. Process for preparing a disaccharide derivative
NL8601551A (nl) * 1985-06-28 1987-01-16 Sandoz Ag Nieuwe saccharides, hun bereiding en farmaceutische samenstellingen, die hen bevatten.
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
JP2839916B2 (ja) * 1989-10-20 1998-12-24 三共株式会社 リピドａ３位エーテル類縁体
DD295854A5 (de) 1989-12-11 1991-11-14 ��@���������@�������k�� Lipid-a-austauschstoffe mit immunoaktivierender und antitumorwirkung
JP2847319B2 (ja) 1990-05-18 1999-01-20 イビデン株式会社 電子部品搭載用多層ボンディング基板
JP3040847B2 (ja) 1990-06-22 2000-05-15 三共株式会社 リピドｘ類縁体
AU660325B2 (en) * 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
US5530113A (en) * 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
JP3135990B2 (ja) 1992-07-31 2001-02-19 沖電気工業株式会社 パリティ付加回路
US5413785A (en) * 1993-01-27 1995-05-09 New England Deaconess Hospital Corp. Methodology employing lactobacillus GG for reduction of plasma endotoxin levels circulating in-vivo
PL181241B1 (pl) * 1993-11-17 2001-06-29 Deutsche Om Arzneimittel Gmbh Disacharydy beta(1 6)glukozoaminowe, sposób wytwarzania disacharydu beta(1 6) glukozoaminowego, zawierająca je kompozycja farmaceutyczna i środek immunomodulujący i/lub przeciwnowotworowy oraz szczepionka
US6417172B1 (en) 1995-06-05 2002-07-09 Eisai Co., Ltd. Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
US5681824A (en) * 1995-06-05 1997-10-28 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
JP4235193B2 (ja) 2005-06-07 2009-03-11 日本電信電話株式会社 イベント履歴蓄積装置、イベント情報検証装置、イベント履歴蓄積方法、イベント情報検証方法およびイベント情報処理システム

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4495346A (en) * 1981-03-30 1985-01-22 Wisconsin Alumni Research Foundation Method of preparing a disaccharide

Also Published As

Publication number Publication date
ZA964666B (en) 1997-03-11
US20030144503A1 (en) 2003-07-31
JPH11506793A (ja) 1999-06-15
RU2170738C2 (ru) 2001-07-20
NZ312299A (en) 1999-08-30
US5750664A (en) 1998-05-12
EP0853627B1 (en) 2004-01-21
HUP9802662A2 (hu) 1999-05-28
ES2214543T3 (es) 2004-09-16
KR19990022104A (ko) 1999-03-25
JP2007269812A (ja) 2007-10-18
IL149971A (en) 2010-04-29
US5935938A (en) 1999-08-10
CA2223140A1 (en) 1996-12-12
NO975644D0 (no) 1997-12-04
CN1192216A (zh) 1998-09-02
AU707779B2 (en) 1999-07-22
EP0853627A1 (en) 1998-07-22
DE69631376D1 (de) 2004-02-26
US6184366B1 (en) 2001-02-06
AU6380296A (en) 1996-12-24
HUP9802662A3 (en) 1999-06-28
JP4009318B2 (ja) 2007-11-14
EP0853627A4 (en) 1998-10-07
CA2223140C (en) 2008-08-05
JP2011121970A (ja) 2011-06-23
US20080214802A1 (en) 2008-09-04
US20020028927A1 (en) 2002-03-07
ATE258185T1 (de) 2004-02-15
NO975644L (no) 1998-02-04
KR100416335B1 (ko) 2004-07-27
IL122251A0 (en) 1998-04-05
MX9709502A (es) 1998-10-31
DK0853627T3 (da) 2004-06-01
HU221342B1 (en) 2002-09-28
US7994154B2 (en) 2011-08-09
US5681824A (en) 1997-10-28
JP4712001B2 (ja) 2011-06-29
WO1996039411A1 (en) 1996-12-12
US20100227835A1 (en) 2010-09-09
TW366345B (en) 1999-08-11
AU707779C (en) 2001-12-06
PT853627E (pt) 2004-05-31
NO310239B1 (no) 2001-06-11
US7737129B2 (en) 2010-06-15
DE69631376T2 (de) 2004-11-11

Similar Documents

Publication Publication Date Title
CN1067082C (zh) 用于治疗和预防内毒素血症的取代的脂多糖
ES2373181T3 (es) Agonistas de gpcr de piperidina.
CN1084623C (zh) 特定的α－半乳糖基神经酰胺、药物组合物及其用途
CN1300165C (zh) 3－β－呋喃核糖基噻唑并[4,5－d]嘧啶核苷及其应用
CN1190097A (zh) 苯基乙基酮衍生物及其制备方法
CN1071668A (zh) 抗内毒素化合物
CN1120153C (zh) 亚吡咯基甲基衍生物及其制备方法
CN1084177A (zh) 具抗病毒和抗癌活性的2′-脱氧-2′，2′-二氟(4-取代嘧啶)核苷以及中间体
CN1568328A (zh) 新的糖脂及其作为有效成分的用于自体免疫疾病的药物
KR102806676B1 (ko) 헤테로아릴로 치환된 피라졸 화합물 및 그의 의약 용도
KR20150022783A (ko) 신규 카르바메이트 당지질 및 그 용도
JPWO2017170826A1 (ja) グルカゴン様ペプチド−１受容体作用増強活性を有する化合物
CN1047869A (zh) 表鬼臼毒吡喃葡糖甙的酰化衍生物
CN1101259A (zh) 新型七叶亭衍生物及医药组合物
CN1208066C (zh) 应用环醚制备影响葡萄糖耐量的药物
CN1210285C (zh) 带取代基的3,6－脱水半乳糖及组合物、食品
HK1046690A1 (en) Novel ribose-substituted aromatic amides, method for the production and use thereof as medicaments
CN1443538A (zh) 抑制人类免疫缺陷综合征病毒感染和增殖的药剂的用途
JPWO2008093655A1 (ja) ポリアルコール化合物および医薬
TWI250162B (en) Beta-lactamase inhibitor prodrug
US20240382470A1 (en) Irak Inhibitor for Treating Cytokine Release-Related Conditions Associated With Infection by a Respiratory Virus
CN1033631A (zh) 表鬼臼毒糖苷4′-酰基衍生物
CN1022570C (zh) 抗病毒化合物的制备方法
CN118005694B (zh) 一种环状核苷类似物及其制备方法和应用
CN87106177A (zh) 唾液酸糖基胆甾醇，它们的制备方法及含有它们的治疗神经病的药物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1038066

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: WEI CAI & D MANAGEMENT CO., LTD.

Free format text: FORMER OWNER: EISAI CO., LTD.

Effective date: 20080314

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20080314

Address after: Tokyo, Japan, Japan

Patentee after: Eisai R. & D. Man Co., Ltd.

Address before: Tokyo, Japan

Patentee before: Eisai co., Ltd.

CX01 Expiry of patent term

Granted publication date: 20010613

EXPY Termination of patent right or utility model